Consensus Cross Country Healthcare, Inc.

Equities

CCRN

US2274831047

Market Closed - Nasdaq 04:30:01 2024-03-18 pm EDT 5-day change 1st Jan Change
17.9 USD +4.50% Intraday chart for Cross Country Healthcare, Inc. -3.97% -20.94%

Evolution of the average Target Price on Cross Country Healthcare, Inc.

Price target over the last 5 years

History of analyst recommendation changes

78f0ce7f4cd682.jUror7TW79unbx4FXNBHSoTXWxHp4DdiMVAMHrFh8zI.3xW96Zm3gr_vXX03Pbokf-qmMVufggA1dhs9XN0Jw0XjG4TB7oCYlYoFTw~ad8786fdc81eba81832dd25d220ef13b
Barrington Cuts Price Target on Cross Country Healthcare to $24 From $26, Keeps Outperform Rating MT
UBS Adjusts Cross Country Healthcare Price Target to $19 From $22, Maintains Neutral Rating MT
Truist Adjusts Cross Country Healthcare's Price Target to $16 From $22, Keeps Hold Rating MT
JMP Securities Initiates Cross Country Healthcare With Market Perform Rating MT
UBS Initiates Coverage on Cross Country Healthcare With Neutral Rating, $22 Price Target MT
Barrington Cuts Price Target on Cross Country Healthcare to $26 From $29, Keeps Outperform Rating MT
Jefferies Downgrades Cross Country Healthcare to Hold From Buy, Adjusts Price Target to $21 From $32 MT
Barrington Cuts Price Target on Cross Country Healthcare to $29 From $35 Amid Reduction in Estimates, Keeps at Outperform MT
Credit Suisse Adjusts Cross Country Healthcare's Price Target to $26 From $27, Keeps Neutral Rating MT
William Blair Initiates Cross Country Healthcare at Outperform Rating MT
Barrington Research Cuts Cross Country Healthcare's Price Target to $35 From $42, Maintains Outperform Rating MT
Credit Suisse Lowers Cross Country Healthcare's Price Target to $27 From $32, Keeps Neutral Rating MT
Truist Securities Adjusts Cross Country Healthcare Price Target to $25 From $38, Maintains Hold Rating MT
Loop Capital Initiates Cross Country Healthcare at Buy Rating With $30 Price Target MT
Barrington Trims Price Target on Cross Country Healthcare to $42 From $45, Reiterates Outperform Rating MT
Benchmark Capital Adjusts Cross Country Healthcare Price Target to $40 From $45, Maintains Buy Rating MT
Credit Suisse Lifts Cross Country Healthcare's Price Target to $32 From $31 After Higher-Than-Expected Q4 Results, Keeps Neutral Rating MT
Barrington Raises Price Target on Cross Country Healthcare to $45 From $41, Affirms Outperform Rating MT
Truist Securities Downgrades Cross Country Healthcare to Hold From Buy; Price Target is $36 MT
Barrington Research Raises Price Target for Cross Country Healthcare to $41 From $40, Maintains Outperform Rating MT
Benchmark Adjusts Price Target on Cross Country Healthcare to $42 From $37, Reiterates Buy Rating MT
Barrington Research Lowers Price Target for Cross Country Healthcare to $40 From $44, Maintains Outperform Rating MT
Benchmark Adjusts Price Target on Cross Country Healthcare to $37 From $42, Reiterates Buy Rating MT
Credit Suisse Adjusts Cross Country Healthcare's PT to $26 from $28, Says Current Market Conditions Hurting Valuations Across Board; Keeps Neutral Rating MT
Barrington Research Hikes PT for Cross Country Healthcare to $44 From $33 as EBITDA Multiple Undervalues Stock, Maintains Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
17.9 USD
Average target price
19.5 USD
Spread / Average Target
+8.94%
High Price Target
24 USD
Spread / Highest target
+34.08%
Low Price Target
16 USD
Spread / Lowest Target
-10.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cross Country Healthcare, Inc.

Barrington Research
UBS
Truist Securities
JMP Securities
Jefferies & Co.
Credit Suisse
William Blair & Co.
Loop Capital
Benchmark Company
Benchmark Capital
BofA Securities
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
  1. Stock
  2. Equities
  3. Stock Cross Country Healthcare, Inc. - Nasdaq
  4. Consensus Cross Country Healthcare, Inc.